The European Food Safety Authority (EFSA) has released its latest report on veterinary drug residues in food sold across the European Union, the regulator's recurring audit of what the region's monitoring programmes find on the plate and, by extension, in the barn.

The report carries weight in three directions at once. It informs European Commission decisions on maximum residue limits (MRLs). It shapes national residue surveillance plans that determine which farms face targeted sampling. And it signals to livestock practitioners where regulatory attention is concentrating — antiparasitics, antibiotics, and other pharmacologically active substances administered to food-producing animals.

What does the report cover?

EFSA's residue reporting consolidates results submitted by EU member states, plus Norway, Iceland and Switzerland, from their national monitoring programmes. Those programmes sample muscle, fat, liver, kidney, milk, eggs and honey from cattle, sheep, pigs, poultry, aquaculture species and other food-producing animals.

The sampling framework distinguishes two tiers:

• Targeted sampling, which directs testing toward animals or products suspected of non-compliance — animals with a treatment history, farm-supply-chain intelligence, or prior violations.
• Random or surveillance sampling, which draws from the general food supply without prior suspicion.

Substances screened include antibacterials, anthelmintics, anticoccidials, carbamates and pyrethroids, sedatives, non-steroidal anti-inflammatory drugs, corticosteroids and other veterinary medicinal products, in line with the EU's residue-control legislation, Directive 96/23/EC and its successor framework under Regulation (EU) 2017/625.

Why does this matter at the farm gate?

For food-animal practitioners, the practical consequences of these reports arrive through withdrawal periods. Every compliance finding — every sample that exceeds an MRL — traces back to a treatment decision: a drug choice, a dose, a dosing interval, or a withdrawal time that the farm did not observe.

Non-compliant results typically trigger follow-up investigations at the holding of origin. Repeat findings can place a farm under intensified sampling, restrict its market access and, in serious cases, invite enforcement. The practitioner's role in documenting treatments and setting withdrawal intervals is the first control point in that entire chain.

What are the companion-animal and public-health angles?

Companion-animal medicine sits outside the residue-monitoring system; dogs and cats do not enter the food chain, and no withdrawal periods attach to their prescriptions. The report's relevance to small-animal practice is indirect but real: residue surveillance and antimicrobial-resistance policy move together in EU regulation, and pressure on agricultural antimicrobial use has steadily reframed antibiotic stewardship conversations in every sector of the profession.

For public health, the reports feed the EU's broader chemical-contaminant surveillance. Residue findings below MRLs are, by regulatory definition, exposures the European system deems safe for consumers; the reports exist to verify that the framework holds under real farming conditions.

What happens next?

The European Commission uses EFSA's consolidated findings to evaluate whether member-state monitoring plans meet EU requirements and to adjust the list of substances and species that require scrutiny. Practitioners who treat food-producing animals in Europe can expect the next annual cycle to continue tracking the same pharmacological groups, with antiparasitics and antibacterials remaining the categories most consistently sampled across member states. The full findings are available through EFSA's publication channel.